Overview

Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease

Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study .
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Axovant Sciences Ltd.
Oxford BioMedica
Collaborator:
Oxford BioMedica